KemPharm, Inc. announced that Richard W. Pascoe, who has been serving as Executive Chairman, will transition into the role of Chief Executive Officer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.45 USD | -2.20% |
|
-10.64% | -32.06% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.06% | 186M | |
+13.67% | 78.98B | |
+13.23% | 8.89B | |
-22.91% | 4.36B | |
+33.84% | 4.29B | |
+10.76% | 4.1B | |
+6.75% | 2.16B | |
-30.28% | 2.13B | |
+8.58% | 2.01B | |
-44.99% | 1.75B |
- Stock Market
- Equities
- ZVRA Stock
- News Zevra Therapeutics, Inc.
- KemPharm, Inc. Appoints Richard W. Pascoe, as Chief Executive Officer